ArticleFrontiers in immunology2026
Multi-country IgE reactivity determination of isoforms of the
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: To produce and purify the two recombinant isoforms rBlo t 2.2 and rBlo t 2.5 and physicochemically characterize them. Methods: Isoforms were expressed in Results: Both isoforms were correctly folded with proper disulfide bonds and exhibited high stability against endolysosomal proteases. Recombinant Blo t 2.2 lacked specific LPS-binding activity and displayed low cross-reactivity with rDer p 2. Across the three countries, the average sensitization rate to rBlo t 2.2 was 50%. Specifically, sensitization was observed in 47% of Brazilian teenagers and 52% of adults, 53% of Colombian individuals, and 48% of Ecuadorian children and teenagers. Sera from the Ecuadorian study exhibited the highest IgE reactivity. The rBlo t 2.2 isoform displayed significantly higher IgE-binding than rBlo t 2.5 in Brazil. Sensitization to rBlo t 2.2 was significantly more frequent in severe asthma patients than in mild asthma and rhinitis patients. Conclusion: rBlo t 2.2 is a stable, mid-tier to major isoform and a candidate biomarker for severe asthma in Brazil. Its structural and immunological characteristics support its inclusion in molecular diagnostic panels. However further investigations with larger sample sizes and application of multivariate analyses are still warranted to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.